Having diabetic retinopathy and/or microalbuminuria predicted a much higher rate of annual decline in glomerular filtration rate (GFR) in a new study of patients with type 2 diabetes living in Japan.
Diabetic retinopathy is a known risk factor for microalbuminuria, and microalbuminuria is a risk factor for macroalbuminuria, but to date it has been unclear whether diabetic retinopathy predicts poor renal function, the authors write.
Scientists at Trinity College Dublin have discovered that a part of the immune system called the inflammasome is involved in regulating the development of one of the most common forms of blindness, called Age-Related Macular Degeneration (AMD). They have discovered that controlling an inflammatory component IL-18, in cases of Age-Related Macular Degeneration (AMD) could prevent…
Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for Research in Vision and Ophthalmology Annual Meeting, being held in Denver, CO. The results from preclinical studies demonstrate that MANF preserves the light-sensing function of photoreceptor cells in a genetic model of…
The promising clinical results obtained for ocular gene therapy in recent years have paved the way for gene supplementation to treat recessively inherited forms of retinal degeneration. We used spliceosome-mediated RNA trans-splicing as a strategy for repairing the transcript of the rhodopsin gene, the gene most frequently mutated in autosomal dominant retinitis pigmentosa (RP). Retinitis…
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization Click here to read more
Bayer HealthCare has entered into a five-year collaboration agreement with The Johns Hopkins University in Baltimore, US, for the discovery and development of new therapies in ophthalmology targeting retinal diseases. Both the parties will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet…
Inhalable and thermo-responsive, fat-encased nanoparticles have been developed by researchers at the University of Sydney as possible treatment for lung cancer. The team has recently designed inhalable, targetable particles that can attack tumors but leave healthy cells undamaged, reducing the side effects of cancer treatment. The particles consist of a drug encased in a lipid…